Genenta Science S.p.A. filings document a foreign private issuer reporting on Form 6-K, with disclosures incorporated by reference into its Form F-3 registration statement when specified. The record covers material events, shareholder voting matters, capital-structure updates, operating and financial results, and clinical or regulatory disclosures for its biotechnology platform and Temferon program.
The filings also document governance and corporate-structure actions, including the approved expansion of the company’s corporate purpose to sectors covered by Italian Golden Power legislation, board changes, listing-compliance notices, material agreements, and decisions to streamline subsidiaries and finance-function arrangements as Genenta pursues an Italy- and Europe-focused industrial aggregator strategy.
Genenta Science S.p.A. (GNTA) received a Nasdaq notice stating that its ADSs did not meet the $1.00 per ADS minimum bid-price requirement after closing bids were below that level for 30 consecutive business days, from September 3, 2026, through October 15, 2026. The notice does not immediately affect the ADSs’ listing or trading on the Nasdaq Capital Market.
Genenta has until April 14, 2027, under an initial 180-calendar-day compliance period. To regain compliance, the ADS closing bid must be at least $1.00 per ADS for a minimum of 10 consecutive business days, unless Nasdaq exercises its discretion to extend this period. Shareholders approved a reverse stock split ratio within a range of 1-for-10 to 1-for-20 and authorized the board, within 12 months of the July 29, 2026, meeting, to decide whether to implement it and set the ratio and effective date.
Genenta Science S.p.A. (GNTA) shareholders did not approve a proposed by-law amendment to change the company’s legal name to Saentra Forge S.p.A. At the October 8, 2026 meeting, 53,307,711 votes were in favor, 20,776,225 were against, and 24,431,835 abstained. Votes in favor represented approximately 54.11% of voting rights represented at the meeting, but approval on first call required a favorable vote of more than 50% of the company’s total voting rights. The company’s registered legal name therefore remains Genenta Science S.p.A.
Genenta says it continues pursuing its previously announced transition to become an industrial consolidator focused on acquiring established public or privately held businesses.
Genenta Science S.p.A. said the Court of Milan denied in full an application by certain minority shareholders for interim relief seeking to suspend the capital increase approved by its board on May 18, 2026, in connection with the ATC acquisition. The capital increase, including the issuance of shares connected with the acquisition, remains effective pending proceedings on the merits and subject to any appeal relating to the order. The civil action remains pending; the order does not finally determine the validity of the challenged resolution or the underlying claims.
Genenta Science S.p.A.’s amended ownership disclosure reports that Fin Posillipo S.p.A. acquired 110,000 ADSs in open-market transactions on Nasdaq from August 7 through August 19, 2026, at $1.30 per ADS for an aggregate purchase price of approximately US$143,000.
The reporting persons may be deemed to beneficially own a combined 5,543,910 Ordinary Shares and ADSs, approximately 11.5% of the outstanding shares and 18.94% of total voting power. The calculation uses 48,216,858 outstanding shares and 109,436,695 outstanding votes, respectively, as of September 29, 2026. The amendment also states that the Court of Milan granted interim relief on June 12, 2026, suspending the effectiveness of an October 29, 2025 resolution concerning the company’s corporate purpose; a court panel revoked that relief on July 9, 2026, and proceedings on the merits remain pending.
Genenta Science S.p.A. (GNTA) reports that its Extraordinary Shareholders’ Meeting held on September 10, 2026, in virtual format did not vote on the proposal to amend Article 1 of its by-laws to change its corporate name to Saentra Forge S.p.A. Shareholders requested a deferral to complete ongoing evaluations of communication, branding, and corporate identity strategy and to allow additional shareholder consultations. The proposal is scheduled to be considered at a reconvened Extraordinary Shareholders’ Meeting on October 8, 2026, at 5:00 p.m. CET.
Genenta Science S.p.A. (GNTA) describes an ongoing transformation from a biotechnology company into a long‑term strategic industrial consolidator focused on acquiring majority or full ownership of privately held, established Italian businesses in national‑security‑regulated sectors, including aerospace, defense, national security and biotechnology/biosecurity.
The company is organized around four pillars: Aerospace, Defense, National Security (including cybersecurity, AI‑driven intelligence, quantum technologies, secure communications and critical infrastructure) and Biotechnology/Biosecurity. In May 2026 it acquired 100% equity ownership of A.T.C. S., a manufacturer of high‑precision tactical rifles and related accessories, and it holds a 19.9% equity interest in Sòphia High Tech S., with a performance‑driven structure that contemplates increasing this stake to 51%. Genenta retains its proprietary cell‑therapy platform but has shifted biotechnology to a partnership‑driven model and does not currently plan to incur material additional clinical‑development costs without a strategic partner or dedicated external financing.
The company is pursuing updated industry classifications so that third‑party taxonomies may reflect an aerospace‑and‑defense‑led industrial business, proposing codes such as FactSet Industry 4420 – Aerospace & Defense and NAICS 336411 – Aircraft Manufacturing, subject to each provider’s review.
Genenta Science S.p.A. reported that an Extraordinary Shareholders’ Meeting held on July 29, 2026 deferred a vote on changing its corporate name to Saentra Forge S.p.A., with the proposal to be reconsidered at a reconvened meeting scheduled for September 10, 2026.
Shareholders granted the Board of Directors five-year authority to increase share capital by up to €300,000,000, including any share premium, issue up to 120,000,000 new ordinary shares and issue convertible bonds under the same aggregate limit. They also approved a potential reverse stock split at a ratio between 1-for-10 and 1-for-20 within 12 months, intended to assist compliance with Nasdaq’s minimum bid price requirement; the Board may decide whether and when to implement it.
Genenta Science S.p.A. reports that the Court of Milan has revoked a preliminary order that had suspended the effectiveness of the amendment to its corporate purpose in Article 4 of its bylaws, approved at the extraordinary shareholders’ meeting held on October 29, 2025.
By order dated July 9, 2026, the Court granted the Company’s precautionary appeal, found that the Company’s interest in maintaining the amendment currently outweighs the alleged prejudice claimed by minority shareholders, and ordered removal of the suspension’s registration from the Italian Companies Register. The corporate purpose amendment is once again fully effective, while the underlying civil action challenging the May 2, 2024 and October 29, 2025 resolutions remains pending, and the Company intends to continue to vigorously defend their validity.
Genenta Science S.p.A. reports outcomes from its June 2026 shareholder meetings and the completion of a strategic acquisition. Shareholders approved the statutory financial statements for the year ended December 31, 2025 and appointed five directors to the Board, with co-founder and CEO Pierluigi Paracchi re-appointed as Chairman.
The Extraordinary Shareholders’ Meeting, which includes proposals to change the corporate name to Saentra Forge S.p.A., delegate to the Board authority to increase share capital under Articles 2443 and 2420-ter of the Italian Civil Code, and execute a share reverse split, was adjourned to July 29, 2026 (first call) and July 30, 2026 (second call) to allow additional shareholder engagement. The record date for voting eligibility remains unchanged.
Genenta also confirms closing of its previously announced transaction to acquire a majority equity interest in Sòphia High Tech S., after receiving the required authorization under Italian “Golden Power” legislation and satisfying all other closing conditions. The transaction terms remain as described in the company’s April 23, 2026 Form 6-K.